Physiotherapeutic recommendations for patients with cystic fibrosis
Keywordscystic fibrosis, treatment methods, physiotherapy
Cystic fibrosis is a genetically determined disease. The development of medicine has resulted in an improvement and prolongation of life. Numerous scientific studies support the thesis that maintaining physical performance is a key element of complex treatment. The basis of treatment should be: parallel pharmacological treatment and physiotherapeutic. The aim of this work was to present the physiotherapeutic techniques used in this disease. The main methods of physiotherapeutic treatment include positional drainage, forced exhalation technique, active breathing cycle technique, autogenous drainage, variable bronchial pressure technique and increased respiratory pressure technique. Physiotherapy of the respiratory system is of major importance, the main aim of which is to prevent the deterioration of the already existing respiratory failure. Each of the presented methods of physiotherapy was created thanks to constant search for the perfect technique to cleanse the bronchial tree. This disease has a different clinical course and each technique should be adapted to the individual needs of the patient and the basis of effective therapy is systematic, daily cleansing of the bronchial mucus from the bronchial tree. Physiotherapy applied earlyIn the thoracic region, it is the treatment of choice for patients with cystic fibrosis, improves the quality of life and prolongs the patient's age.
1. There is no effective, causal treatment for cystic fibrosis, and drug treatment comes down to treating complications and often has side effects.
2. Comprehensive physiotherapy is the golden mean in the treatment of cystic fibrosis and significantly prolongs the life of patients.
3. The effectiveness of physiotherapy depends on the time of commencement, regularity and personalization of treatments.
Alton E., Amstrong D., Ashby Di et al .: Repeated nebulization of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomized, double blind, placebo-controlled, phase 2b trial. Lancet Resp Med. 2015, 3 (9), 684-691.
Bal - Bocheńska M., Wolan A., Kwolek A .: Assessment of the effectiveness of airway clearance in children suffering from cystic fibrosis. Medical Review URz, 2009, 1: 31-36.
Burgener EB, Moss R.: Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Curr Opin Pediatr., 2018, 30 (3), 372-377.
Castellani C., Assael BM: Cystic fibrosis and clinical review. Cell Mol Live Sci, 2017, 74 (1), 129-140.
Demczyszak I., Kuciel-Lewandowska J., Paprocka-Borowicz M .: Physiotherapy in respiratory diseases. In Górnicki. 2009, 31-33.
Dolecki W., Rongies W .: Rehabilitation in obstructive airway diseases. Therapy, 2003, 2.
Domeńska H .: Lung transplants in patients with cystic fibrosis. Borgis, Advances in medical science, 2008, 9,601-605.
Elborn JS: Cystic fibrosis. Lancet, 2016, 19, 388 (10059), 2519-2531.
Gill DR, Hyde SC: Delivery of genes into the CF airway. Thorax, 2014, 69, 962-964.
Gutowski P .: Functional tests of the respiratory system in children. Borgis, Advances in medical science, 2008.9, 559-564.
Hoo ZH, Daniels T., Wildman NJ ad all: Airway clearance techniques used by people with CF in the UK. Physiotherapy 2015, 101 (4), 340-348.
Małolepsza K .: Physiotherapy in children suffering from cystic fibrosis. New Pediatrics, 2000, 5, 14-15.
McIIwaine MP, Lee Son NM, Lynn Richmond M .: Physiotherapy and cystic fibrosis: what is the evidence base. Curr Opin Pulm Med. 2014, 20, 613-617.
Orlik T .: Evaluation of the effectiveness of selected methods of chest physiotherapy used in the treatment of patients with cystic fibrosis. Med. Developmental Age. 2000: 3: 233-245.
Orlik T., Malinowski A., Skorupa W. et al .: Long-term model of physiotherapeutic treatment in cystic fibrosis. Position of the Polish Working Group. Matio, 2003, 4, 4-9.
Rachword TL, Teckman JH, Patel DR: Gastrointestinal pathophysiology and nutrition in cystic fibrosis. Expert Rev Gastroenterol Hepatol. 2018, 12 (9), 853-862.
Rosławski A., Woźniewski M .: Respiratory physiotherapy. AWF Wrocław. 2001, 44-57.
Saimon L., Schechter M .: Evaluating Long-Term Benefits of Chronic Azithromycin. Futhering Our Quest for Precision Medicine. Am J Resp Crit. Care Med. 2020, 15, 201 (4), 398-400.
Sala MA, Jain M .: Tezacaftor for treatment of cistic fibrosis. Expert Rev. Resp. Med. 2018, 12 (9), 725-732.
Souther KW, Barker PM: Azitromycin for cystic fibrosis. Eur. Resp. J. 2004, 24, 834-835.
Starner T., McCray P .: Pathogenesis of Early Lung Disease in Cystic Fibrosis. A Window of Oportunity to Eradicate Bacteria. Annals of Internal Medicine. ACP, 2005.
Szczeklik A .: Internal diseases. MP Krakow. 2010, 610-612.
Walkowiak J., Pogorzelski A., Sands D. et al .: Principles of diagnosis and treatment of cystic fibrosis. Poznań-Warsaw-Rzeszów. Medical Standards. 2009.
Zieliński J .: Genotype and phenotype in cystic fibrosis. Respiration. 2000, 67 (2), 117-133.
How to Cite
LicenseThe periodical offers access to content in the Open Access system under the Creative Commons non-exclusive license (CC BY-ND 4.0).
Number of views and downloads: 3
Number of citations: 0